Andrew Coleman, MD
Internal Medicine · Paris, TNNPI 1770565459
Payments from drug & device makers
Across 197 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$509
- Novo Nordisk$481
- Merck$408
- Amgen$188
- AbbVie$173
- Sanofi-aventis U.S. LLC$112
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $509 |
| Novo Nordisk | 29 | $481 |
| Merck | 29 | $408 |
| Amgen | 13 | $188 |
| AbbVie(2 entities) | 10 | $173 |
| Sanofi-aventis U.S. LLC | 7 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| AstraZeneca | 5 | $83 |
| Amarin Pharma, Inc. | 5 | $77 |
| Boehringer Ingelheim | 4 | $76 |
| Dexcom, Inc. | 5 | $75 |
| GSK | 5 | $69 |
| Astellas Pharma US Inc | 4 | $67 |
| Lilly USA, LLC | 3 | $64 |
| Novartis | 4 | $62 |
| Johnson & Johnson | 4 | $59 |
| Mylan Specialty L.p. | 4 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Abbott | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Exact Sciences | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$3,012 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 738 | $303,303 |
| OzempicSemaglutide | 188 | $214,330 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $90,050 |
| JardianceEmpagliflozin | 245 | $73,116 |
| JanuviaSitagliptin Phosphate | 127 | $65,268 |
| TrulicityDulaglutide | 44 | $63,825 |
| XareltoRivaroxaban | 149 | $60,932 |
| NuplazidPimavanserin Tartrate | 44 | $54,259 |
| FarxigaDapagliflozin Propanediol | 35 | $40,377 |
| LinzessLinaclotide | 61 | $38,499 |
| MyrbetriqMirabegron | 157 | $30,853 |
| MounjaroTirzepatide | 27 | $30,818 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $27,136 |
| XolairOmalizumab | 12 | $20,887 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $17,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $509 | $313,507750 claims |
| Novo NordiskOzempic, Novolog | $481 | $222,624235 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $69 | $134,838208 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $64 | $94,64371 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $76 | $81,143260 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $83 | $65,688119 claims |
| MerckJanuvia | $408 | $65,268127 claims |
| Johnson & JohnsonXarelto | $59 | $60,932149 claims |
| AbbVieLinzess | $173 | $38,49961 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $30,853157 claims |
| NovartisEntresto | $62 | $13,53216 claims |
| Sanofi-aventis U.S. LLCLantus | $112 | $12,440148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Paris
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.